Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Receivables (2016 - 2025)

Historic Receivables for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to $26.8 million.

  • Gyre Therapeutics' Receivables rose 2846.72% to $26.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.8 million, marking a year-over-year increase of 2846.72%. This contributed to the annual value of $24.2 million for FY2024, which is 4676.55% up from last year.
  • Gyre Therapeutics' Receivables amounted to $26.8 million in Q3 2025, which was up 2846.72% from $25.4 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Receivables high stood at $26.8 million for Q3 2025, and its period low was $564000.0 during Q1 2022.
  • Its 5-year average for Receivables is $12.4 million, with a median of $15.2 million in 2023.
  • In the last 5 years, Gyre Therapeutics' Receivables tumbled by 4512.53% in 2021 and then skyrocketed by 84257.43% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Receivables (Quarter) stood at $1.8 million in 2021, then skyrocketed by 842.57% to $17.1 million in 2022, then dropped by 11.51% to $15.2 million in 2023, then surged by 59.35% to $24.2 million in 2024, then grew by 10.79% to $26.8 million in 2025.
  • Its last three reported values are $26.8 million in Q3 2025, $25.4 million for Q2 2025, and $22.5 million during Q1 2025.